Taiyen Biotech Co Ltd (1737) - Net Assets
Based on the latest financial reports, Taiyen Biotech Co Ltd (1737) has net assets worth NT$6.81 Billion TWD (≈ $214.67 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$8.26 Billion ≈ $260.32 Million USD) and total liabilities (NT$1.45 Billion ≈ $45.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Taiyen Biotech Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$6.81 Billion |
| % of Total Assets | 82.47% |
| Annual Growth Rate | -0.33% |
| 5-Year Change | 4.61% |
| 10-Year Change | 13.82% |
| Growth Volatility | 4.48 |
Taiyen Biotech Co Ltd - Net Assets Trend (2003–2025)
This chart illustrates how Taiyen Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Taiyen Biotech Co Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Taiyen Biotech Co Ltd (2003–2025)
The table below shows the annual net assets of Taiyen Biotech Co Ltd from 2003 to 2025. For live valuation and market cap data, see market cap of Taiyen Biotech Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$6.81 Billion ≈ $214.67 Million |
+2.19% |
| 2024-12-31 | NT$6.67 Billion ≈ $210.07 Million |
+1.81% |
| 2023-12-31 | NT$6.55 Billion ≈ $206.32 Million |
-1.70% |
| 2022-12-31 | NT$6.66 Billion ≈ $209.89 Million |
+2.28% |
| 2021-12-31 | NT$6.51 Billion ≈ $205.21 Million |
+2.34% |
| 2020-12-31 | NT$6.36 Billion ≈ $200.51 Million |
+3.44% |
| 2019-12-31 | NT$6.15 Billion ≈ $193.85 Million |
-0.05% |
| 2018-12-31 | NT$6.16 Billion ≈ $193.93 Million |
+2.28% |
| 2017-12-31 | NT$6.02 Billion ≈ $189.62 Million |
+0.54% |
| 2016-12-31 | NT$5.99 Billion ≈ $188.60 Million |
+2.14% |
| 2015-12-31 | NT$5.86 Billion ≈ $184.65 Million |
+0.62% |
| 2014-12-31 | NT$5.82 Billion ≈ $183.52 Million |
+1.58% |
| 2013-12-31 | NT$5.73 Billion ≈ $180.67 Million |
-12.13% |
| 2012-12-31 | NT$6.53 Billion ≈ $205.60 Million |
-1.26% |
| 2011-12-31 | NT$6.61 Billion ≈ $208.23 Million |
+0.43% |
| 2010-12-31 | NT$6.58 Billion ≈ $207.34 Million |
+0.21% |
| 2009-12-31 | NT$6.57 Billion ≈ $206.92 Million |
+3.30% |
| 2008-12-31 | NT$6.36 Billion ≈ $200.31 Million |
-4.13% |
| 2007-12-31 | NT$6.63 Billion ≈ $208.94 Million |
-4.74% |
| 2006-12-31 | NT$6.96 Billion ≈ $219.34 Million |
+0.90% |
| 2005-12-31 | NT$6.90 Billion ≈ $217.39 Million |
-12.06% |
| 2004-12-31 | NT$7.85 Billion ≈ $247.21 Million |
+7.06% |
| 2003-12-31 | NT$7.33 Billion ≈ $230.91 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Taiyen Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$823.82 Million | 12.09% |
| Common Stock | NT$2.00 Billion | 29.35% |
| Other Comprehensive Income | NT$1.50 Billion | 22.07% |
| Other Components | NT$2.49 Billion | 36.49% |
| Total Equity | NT$6.81 Billion | 100.00% |
Taiyen Biotech Co Ltd Competitors by Market Cap
The table below lists competitors of Taiyen Biotech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dynamix Corporation III Class A Ordinary Shares
NASDAQ:DNMX
|
$200.85 Million |
|
Bergbahnen Engelberg Truebsee Titlis Bet AG
SW:TIBN
|
$200.93 Million |
|
Maritime Resources Corp.
V:MAE
|
$200.98 Million |
|
Yantai Changyu Pioneer Wine
SHE:200869
|
$201.01 Million |
|
Jw Holdings
KO:096760
|
$200.69 Million |
|
RCI Hospitality Holdings Inc
NASDAQ:RICK
|
$200.66 Million |
|
GENFIT S.A. ADR/1 EO-25
F:XUPB
|
$200.59 Million |
|
X-Legend Entertainment Co Ltd
TW:4994
|
$200.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Taiyen Biotech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,664,089,000 to 6,813,768,000, a change of 149,679,000 (2.2%).
- Net income of 399,867,000 contributed positively to equity growth.
- Dividend payments of 260,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 1,506,313,999.
- Other factors decreased equity by 1,496,501,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$399.87 Million | +5.87% |
| Dividends Paid | NT$260.00 Million | -3.82% |
| Other Comprehensive Income | NT$1.51 Billion | +22.11% |
| Other Changes | NT$-1.50 Billion | -21.96% |
| Total Change | NT$- | 2.25% |
Book Value vs Market Value Analysis
This analysis compares Taiyen Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.92x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$32.81 | NT$31.85 | x |
| 2010-12-31 | NT$32.87 | NT$31.85 | x |
| 2011-12-31 | NT$33.02 | NT$31.85 | x |
| 2012-12-31 | NT$23.44 | NT$31.85 | x |
| 2013-12-31 | NT$28.57 | NT$31.85 | x |
| 2014-12-31 | NT$29.09 | NT$31.85 | x |
| 2015-12-31 | NT$29.24 | NT$31.85 | x |
| 2016-12-31 | NT$29.85 | NT$31.85 | x |
| 2017-12-31 | NT$30.02 | NT$31.85 | x |
| 2018-12-31 | NT$30.67 | NT$31.85 | x |
| 2019-12-31 | NT$30.68 | NT$31.85 | x |
| 2020-12-31 | NT$31.06 | NT$31.85 | x |
| 2021-12-31 | NT$31.72 | NT$31.85 | x |
| 2022-12-31 | NT$32.50 | NT$31.85 | x |
| 2023-12-31 | NT$32.38 | NT$31.85 | x |
| 2024-12-31 | NT$33.22 | NT$31.85 | x |
| 2025-12-31 | NT$34.62 | NT$31.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Taiyen Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.87%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.09%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.21x
- Recent ROE (5.87%) is above the historical average (5.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 13.11% | 27.51% | 0.30x | 1.57x | NT$227.85 Million |
| 2004 | 13.13% | 27.58% | 0.38x | 1.25x | NT$245.62 Million |
| 2005 | 0.22% | 0.53% | 0.38x | 1.13x | NT$-674.55 Million |
| 2006 | 4.92% | 12.71% | 0.36x | 1.07x | NT$-353.85 Million |
| 2007 | 0.71% | 2.01% | 0.33x | 1.06x | NT$-616.20 Million |
| 2009 | 3.19% | 10.59% | 0.29x | 1.05x | NT$-447.00 Million |
| 2010 | 2.76% | 8.43% | 0.31x | 1.06x | NT$-476.71 Million |
| 2011 | 2.94% | 8.44% | 0.33x | 1.05x | NT$-466.88 Million |
| 2012 | 1.20% | 3.40% | 0.33x | 1.05x | NT$-574.49 Million |
| 2013 | 2.20% | 5.23% | 0.39x | 1.08x | NT$-447.51 Million |
| 2014 | 3.68% | 8.26% | 0.39x | 1.16x | NT$-368.03 Million |
| 2015 | 4.59% | 9.74% | 0.40x | 1.17x | NT$-317.17 Million |
| 2016 | 5.88% | 12.77% | 0.39x | 1.18x | NT$-246.67 Million |
| 2017 | 5.88% | 12.83% | 0.38x | 1.20x | NT$-248.16 Million |
| 2018 | 7.35% | 15.08% | 0.41x | 1.19x | NT$-162.82 Million |
| 2019 | 5.62% | 11.89% | 0.38x | 1.24x | NT$-269.78 Million |
| 2020 | 5.86% | 11.66% | 0.40x | 1.25x | NT$-257.86 Million |
| 2021 | 6.18% | 9.60% | 0.48x | 1.33x | NT$-242.89 Million |
| 2022 | 6.54% | 11.81% | 0.44x | 1.26x | NT$-225.42 Million |
| 2023 | 4.63% | 8.81% | 0.41x | 1.28x | NT$-348.74 Million |
| 2024 | 5.58% | 11.47% | 0.39x | 1.26x | NT$-294.88 Million |
| 2025 | 5.87% | 12.09% | 0.40x | 1.21x | NT$-281.51 Million |
Industry Comparison
This section compares Taiyen Biotech Co Ltd's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $1,989,526,444
- Average return on equity (ROE) among peers: 10.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Taiyen Biotech Co Ltd (1737) | NT$6.81 Billion | 13.11% | 0.21x | $200.69 Million |
| Farcent Enterprise Co Ltd (1730) | $1.92 Billion | 13.23% | 0.35x | $104.59 Million |
| Mao Bao Inc (1732) | $501.11 Million | 2.78% | 0.36x | $34.50 Million |
| Sanitar Co Ltd (1817) | $1.80 Billion | 12.28% | 0.51x | $87.65 Million |
| Shihlin Paper Corp (1903) | $4.55 Billion | -2.69% | 0.92x | $405.13 Million |
| Jia Wei Lifestyle Inc (3557) | $1.19 Billion | -23.77% | 0.50x | $80.62 Million |
| Chlitina Holding Ltd (4137) | $4.11 Billion | 29.63% | 0.55x | $276.79 Million |
| Jourdeness Group Ltd (4190) | $422.64 Million | 37.79% | 4.20x | $47.29 Million |
| Kuangli Photoelectric Technology Co Ltd (6431) | $742.47 Million | 7.54% | 0.68x | $59.84 Million |
| Nan Liu Enterprise Co Ltd (6504) | $2.66 Billion | 21.83% | 1.02x | $90.23 Million |
About Taiyen Biotech Co Ltd
Taiyen Biotech Co., Ltd. engages in the production and sale of salt products in Taiwan and internationally. It offers beauty and skincare, and cleaning products; salt products; and leisure and pet foods, as well as health supplement. The company was founded in 1952 and is based in Tainan City, Taiwan.